The RU486 continues to kill
Nadine Walkowiak was in 1991 the first known victim of RU486 in
France. The International
Commission of Inquiry that we instigated in 1990 had already warned that this drug was a huge technical error and
that it would kill a lot of women. Health authorities at
that time, mostly concerned with ideologies, disregarded the
warning. The same applied to their successors and the press that
acted upon their orders.
- Sept.01, 2001: in Vancouver (Canada, B.C.) a woman died as a result of gangrene that started in her uterus compromising vital organs and causing heart failure. Nine days before that, she had taken the RU486 + misoprostol (Cytotec) during a clinical trial. That clinical trial campaign orchestrated by the Population Council has been suspended.
- Sept. 12, 2001at Hamilton County (USA, TN), Brenda A. Vise, 38 years old, died of a mass infection due to a ruptured ectopic pregnancy, 5 days before, she had taken the RU486 at the Knoxville abortion clinic, which did not detect the extra-uterine nature of her pregnancy, despite the ultra sound. Court case.
- Nov. 16, 2002: in Alexandria (USA, VA), a woman aged 26 died from a "medical procedure" at the abortion clinic Landmark Women's Center, which used the RU486. The clinic is withholding information but the use of RU486 is suspected.
- June 3, 2003: in Uddevalla, Sweden, Rebecca Tell Berg, aged 16, died after taking the RU486 (Mifegyne) + Cytotec. She was found in the shower. She bled to death. The procedure had been carried out following instructions precisely.
Sept. 17, 2003: in Hayward (USA, CA), Holly Patterson, 18 years old, died after she visited the Family Planning Center and took the RU486: Uterine infection. For once, the media coverage was important: The parents not knowing what was really happening, expressed their sorrow and anger.
- In January 2004, we learnt by the British Health Minister that since 1991, 2 women had died because of RU486 in Great Britain (2 reports on "suspected fatal reactions in association with Mifegyne.") This information, most likely truncated, was filtered due to a formal parliamentary question triggered by the Holly Patterson case.
- Jan. 8, 2004: in Detroit (USA, MI), Tamia Russell, 15 years old, dies as a consequence of an abortion in the second quarter of pregnancy. The RU486 is thought to have caused the fatal infection; there had been a uterine infarction. Her parents did not know about the abortion despite the local law requirement on parental consent.
- Oct. 22, 2001: The Chinese Communist State forbids the sale of RU486 in pharmacies. Even if the local press does not mention it, such a decision is certainly a result of the death of dozens of women killed by the product; communist authorities have already demonstrated their lack of transparency in the case of avian influenza.
Manufacturer Roussel-Uclaf, of the Hoechst group (former IG-Farben, now called Aventis) withdrew from the production of poisonous RU486 while offering it as a gift to his former leader Sakiz (Exelgyn) and to the eugenics organization whose pockets are full of dollars: the Population Council.
The production is now guaranteed for Europe by the American group PPG Industries which manufactures the drug in France, near Angers; and for China and the Americas by the Zizhu group in Shanghai. A new French-Chinese alliance (Synergis Pharma) is trying to compete with the French godfather.
In France, since 1991, date of Nadine’s death, no new French victims could filter into the press. The omertà is almost total, but we can reasonably estimate, that dozens of women have died because of the RU 486, like in Great Britain. It is quite easy to only declare the alleged cause of death (infection, heart disease, etc.), especially if the interests of "Family" Planning associations and the abortion syndicate, and of course, that of the State which supports them, are at stake.
All the above does not prevent them from claiming the distribution of the poison in pharmacies in the name of “women’s health.” Today's French government is completely at their service and it has committed itself to publishing its application at the beginning of July 2004.
Thierry LEFÈVRE © TDD July 2004